| Nov 17 |
Elevai Labs Third Quarter 2024 Earnings: US$0.068 loss per share (vs US$0.078 loss in 3Q 2023)
|
| Nov 14 |
CORRECTION - Elevai Labs Inc.
|
| Nov 14 |
Elevai Labs Inc. Reports Financial Results for the Second Fiscal Quarter of 2024 and Provides Business Update
|
| Nov 14 |
Why DLocal Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket
|
| Nov 4 |
Elevai Labs announces update and extension of pending offer to exchange shares of common stock
|
| Nov 4 |
Elevai Labs Inc. Announces Update and Extension of Pending Offer to Exchange
|
| Nov 1 |
Why Charter Communications Shares Are Trading Higher By Around 11%; Here Are 20 Stocks Moving Premarket
|
| Oct 31 |
Why Carvana Shares Are Trading Higher By Around 20%; Here Are 20 Stocks Moving Premarket
|
| Oct 22 |
Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Engages Leading Contract Research Organization (CRO) to Support Regulatory Planning Efforts and Pre-IND Meeting with the Food and Drug Administration For EL-22 For The Treatment of Obesity
|
| Oct 21 |
Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Highlights Past Positive Preclinical Data Showing Potential of EL-32, A Dual Myostatin & Activin-A Blocker, For the Treatment of Obesity
|
